Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Дозирование антибиотиков у пациентов с сепсисом, которым проводится заместительная почечная терапия

https://doi.org/10.33667/2078-5631-2019-1-16(391)-47-57

Полный текст:

Аннотация

У больных, находящихся в критическом состоянии, адекватность стартовой эмпирической антимикробной терапии является определяющим фактором выживания пациентов с сепсисом. В статье рассмотрены основные аспекты эмпирического назначения антибиотиков у пациентов с сепсисом, находящихся на заместительной почечной терапии. Описаны изменения механизмов фармакокинетики и фармакодинамики, которые приводят к выбору особых режимов дозирования антибиотиков. Представлена информация об изменении дозирования для актуальных групп антибактериальных препаратов. Целью данной статьи является рационализация антибактериальной терапии у выбранной группы пациентов.

Об авторах

А. О. Шалгинских
ФГБНУ «Российский научный центр хирургии имени акад. Б. В. Петровского»
Россия
г. Москва


С. В. Яковлев
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава России
Россия
г. Москва


Д. Н. Проценко
ГБУЗ «Городская клиническая больница имени С. С. Юдина» Департамента здравоохранения города Москвы
Россия


И. Н. Сычев
ГБУЗ «Городская клиническая больница имени С. С. Юдина» Департамента здравоохранения города Москвы
Россия


М. П. Суворова
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава России
Россия
г. Москва


А. О. Быков
ГБУЗ «Городская клиническая больница имени С. С. Юдина» Департамента здравоохранения города Москвы
Россия


Список литературы

1. Lewis SJ, Mueller BA. Antibiotic dosing in patients with acute kidney injury: ‘‘Enough But Not Too Much’’. J Intensive Care Med 2016:31(3):164–176.

2. Sime F. B., Roberts M. S., Roberts J. A. Optimization of dosing regimens and dosing in special populations. Clin Microbiol Infect 2015;21(10):886–893. doi:10.1016/j.cmi.2015.05.002

3. Jamal J-A, Mueller BA, Choi GYS, Lipman J, Roberts JA. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis 2015;82(1):92–103.

4. Tsai D, Lipman J, Roberts JA. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. Curr Opinion in Critical Care 2015;21(5):412–420.

5. Wong WT, Choi G, Gomersall CD, Lipman J. To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt. Curr Opin Pharmacol 2015;24:68–78.

6. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients. Clin Pharmacokin 2011; 50(2):99–110.

7. Sime FB, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients: etiology, definition and implication for beta-lactam dose optimization. Curr Opin Pharmacol 2015;24:1–6.

8. Roberts JA, Udy AA, Jarrett P, Wallis SC, Hope WW, Sharma R, et al. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. J Antimicrob Chemother 2015;70(5): 1495–1502.

9. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 37(7):2268–2282.

10. Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, et al. ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiology 2012;12(1):12–29

11. Wong W-T, Choi G, Gomersall C. D, Lipman J. To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt. Curr Opin Pharmacol 2015;24:68–78.

12. Kadri SS, Rhee C, Strich JR, Morales MK, Hohmann S, Menchaca J, et al. Estimating Ten-Year Trends in Septic Shock Incidence and Mortality in United States Academic Medical Centers Using Clinical Data. Chest 2017;151(2):278–285.

13. Yébenes JC, Ruiz-Rodriguez JC, Ferrer R, Clèries M, Bosch A, Artigas A. Epidemiology of sepsis in Catalonia: analysis of incidence and outcomes in a European setting. Ann Intensive Care 2015;7(1). doi:10.1186/s13613–017–0241–1

14. Nisula S, Kaukonen K-M, Vaara ST, Korhonen A-M, Poukkanen M, Pettilä V. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Med 2013;39(3): 420–428.

15. Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015; 41(8),:1411–1423

16. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013;17(1):204.

17. Edrees F, Li T, Vijayan A. Prolonged Intermittent Renal Replacement Therapy. Adv Chron Kidney Dis 2016; 23(3):195–202.

18. Macedo E, Mehta RL. Continuous Dialysis Therapies: Core Curriculum 2016. Amer J Kidney Dis 2016;68(4):645–657.

19. Saline versus Albumin Fluid Evaluation Study Investigators. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ 2006;333(7577):1044–1049. doi:10.1136/bmj.38985.398704.7c

20. Ulldemolins M, Vaquer S, Llauradó-Serra M, Pontes C, Calvo G, Soy D, Martín-Loeches I. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy. Crit Care 2014;18(3):227.

21. Romagnoli S, Clark WR, Ricci Z, Ronco C. Renal replacement therapy for AKI: When? How much? When to stop? Best Pract Research Clin Anaesthesiol 2017;31(3): 371–385.

22. Fayad AI, Buamscha DG, Ciapponi A. Intensity of continuous renal replacement therapy for acute kidney injury. Cochrane Database of Systematic Reviews 2016. doi:10.1002/14651858.cd010613.pub2.

23. Руководство Всемирной федерации обществ анестезиологов (WFSA): Основы интенсивной терапии / Bruce McCormick. Пер англ. под ред. В. В. Кузькова, Э. В. Недашковского. Издание 2-е, переработанное и дополненное, 2016 — Гл. VIII. — с. 375–378

24. Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy. Crit Care Med 2012;40(5):1523–1528.

25. Goldstein S. L, Nolin TD. Lack of Drug Dosing Guidelines for Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Clin Pharmacol Therap 2014;96(2),159–161.

26. Awdishu L, Bouchard J. How to Optimize Drug Delivery in Renal Replacement Therapy. Seminars Dialysis 2011;24(2):176–182.

27. Hsaiky L, Murray K P, Kokoska L, Desai N, Cha R. Standard Versus Prolonged Doripenem Infusion for Treatment of Gram-Negative Infections. Ann Pharmacother 2013;47(7–8): 999–1006.

28. Bauer, K. A., West, J. E., O’Brien, J. M., Goff, D. A. Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother 2013;57(7): 2907–2912.

29. Teo, J., Liew, Y., Lee, W., Kwa, A. L.-H. Prolonged infusion versus intermittent boluses of β-lactam antibiotics for treatment of acute infections: a meta-analysis. Intern J Antimicrob Agents 2014; 43(5): 403–411. doi:10.1016/j.ijantimicag.2014.01.027

30. Huttner, A., Von Dach, E., Renzoni, A., Huttner, B. D., Affaticati, M., Pagani, L., et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study. Intern J Antimicrob Agents 2015; 45(4): 385–392.

31. Ulldemolins M, Vaquer S, Llauradó-Serra M, Pontes C, Calvo G, Soy D and Martín-Loeches I. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy Crit Care 2014;18:227

32. Bauer, S. R., Salem, C., Connor, M. J., Groszek, J., Taylor, M. E., Wei, P., et al. Pharmacokinetics and Pharmacodynamics of Piperacillin-Tazobactam in 42 Patients Treated with Concomitant CRRT. Clin J Amer Soc Nephrology 2012; 7(3): 452–457.

33. Bilgrami, I., Roberts, J. A., Wallis, S. C., Thomas, J., Davis, J., Fowler, S., et al. Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration. Antimicrob Agents Chemother 2010; 54(7): 2974–2978.

34. Roberts, J. A., Udy, A. A., Bulitta, J. B., Stuart, J., Jarrett, P., Starr, T., et al. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. J Antimicrob Chemother 2014; 69(9): 2508–2516.

35. Eyler, R. F., Vilay, A. M., Nader, A. M., Heung, M., Pleva, M., Sowinski, K. M., et al. Pharmacokinetics of Ertapenem in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis or Hemodiafiltration. Antimicrob Agents Chemother 2013; 58(3): 1320–1326.

36. Jamal, J.-A., Mat-Nor, M.-B., Mohamad-Nor, F.-S., Udy, A. A., Wallis, S. C., Lipman, J., & Roberts, J. A. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. Intern J Antimicrob Agents 2015 45(1):41–45.

37. De Montmollin, E., Bouadma, L., Gault, N., Mourvillier, B., Mariotte, E., Chemam, S., et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Medicine 2014; 40(7): 998–1005.

38. De Rosa, F. G., & Roberts, J. A. Amikacin dosing in the ICU: we now know more, but still not enough… Intensive Care Med 2014; 40(7): 1033–1035.

39. Akers, K. S., Cota, J. M., Frei, C. R., Chung, K. K., Mende, K., & Murray, C. K. Once-Daily Amikacin Dosing in Burn Patients Treated with Continuous Venovenous Hemofiltration. Antimicrob Agents Chemother 2011; 55(10): 4639–4642.

40. D’Arcy, D. M., Casey, E., Gowing, C. M., Donnelly, M. B., & Corrigan, O. I. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. BMC Pharmacol Toxicol 2012; 13(1).

41. Taccone, F. S., de Backer, D., Laterre, P.-F., Spapen, H., Dugernier, T., Delattre, I., et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Intern J Antimicrob Agents 2011; 37(6): 531–535.

42. Spooner, A. M., Deegan, C., D’Arcy, D. M., Gowing, C. M., Donnelly, M. B., & Corrigan, O. I. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. BMC Clin Pharmacol 2011; 11(1).

43. Swoboda, S., Ober, M. C., Lichtenstern, C., Saleh, S., Schwenger, V., Sonntag, H.-G., et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Europ J Clin Pharmacol 2009 66(3): 291–298.

44. Tafelski, S., Nachtigall, I., Troeger, U., Deja, M., Krannich, A., Günzel, K., & Spies, C. Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: Continuous versus intermittent application. J Infect Public Health 2015 8(4): 355–363.

45. Matsumoto, K., Kanazawa, N., Watanabe, E., Yokoyama, Y., Fukamizu, T., Shimodozono, Y., et al. Development of Initial Loading Procedure for Teicoplanin in Critically Ill Patients with Severe Infections. Biolog Pharmaceut Bull 2013; 36(6): 1024–1026.

46. Beumier, M., Roberts, J. A., Kabtouri, H., Hites, M., Cotton, F., Wolff, F., et al. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother 2013; 68(12): 2859–2865.

47. Escobar, L., Andresen, M., Downey, P., Gai, M. N., Regueira, T., Bórquez, T., et al. Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. Intern J Antimicrob Agents 2014; 44(2):163–167.

48. Beumier, M., Roberts, J. A., Kabtouri, H., Hites, M., Cotton, F., Wolff, F., et al. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother 2013; 68(12): 2859–2865.

49. Vessal, G., Sagheb, M. M., Shilian, S., Jafari, P., & Samani, S. M. Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. Nephrology Dialysis Transplantation 2009; 25(5):1541–1547.

50. Wenisch, J. M., Meyer, B., Fuhrmann, V., Saria, K., Zuba, C., Dittrich, P., & Thalhammer, F. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother 2011; 67(4): 977–983.

51. D. Khadzhynov, T. Slowinski, I. Lieker, C. Spies, B. Puhlmann, T. König, et al. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD Int. Journal of Clinical Pharmacology and Therapeutics, Volume 49 — November (656–665)

52. Nation, R. L., Garonzik, S. M., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Forrest, A., Paterson, D. L., et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis 2016, doi:10.1093/cid/ciw839

53. Vardakas, K. Z., Mavroudis, A. D., Georgiou, M., & Falagas, M. E. Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: A systematic review and meta-analysis. Journal of Infection 2018; 76(4): 321–327.

54. Vardakas, K. Z., Mavroudis, A. D., Georgiou, M., & Falagas, M. E. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. Intern J Antimicrob Agents 2018; 51(4): 535–547.

55. Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M., & Rolain, J.-M. Colistin: an update on the antibiotic of the 21st century. Expert Review of Anti-Infective Therapy 2012;10(8): 917–934.

56. Karvanen, M., Plachouras, D., Friberg, L. E., Paramythiotou, E., Papadomichelakis, E., Karaiskos, I., et al. Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration. Antimicrob Agents Chemother 2012 57(1): 668–671.

57. Markou, N., Fousteri, M., Markantonis, S. L., Zidianakis, B., Hroni, D., Boutzouka, E., & Baltopoulos, G. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 2012; 67(10): 2459–2462.

58. Honoré, P. M., Jacobs, R., De Regt, J., Van Gorp, V., De Waele, E., & Spapen, H. D. Colistin dosing for treatment of multidrug-resistant Pseudomonas in critically ill patients — please, be adequate! Crit Care 2014; 18(1): 412.


Для цитирования:


Шалгинских А.О., Яковлев С.В., Проценко Д.Н., Сычев И.Н., Суворова М.П., Быков А.О. Дозирование антибиотиков у пациентов с сепсисом, которым проводится заместительная почечная терапия. Медицинский алфавит. 2019;1(16):47-57. https://doi.org/10.33667/2078-5631-2019-1-16(391)-47-57

For citation:


Shalginskikh A.O., Yakovlev S.V., Protsenko D.N., Sychev I.N., Suvorova M.P., Bykov A.O. Dosing of antibiotics in patients with sepsis, including those undergoing renal replacement therapy. Medical alphabet. 2019;1(16):47-57. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-16(391)-47-57

Просмотров: 396


ISSN 2078-5631 (Print)